SURVIMED OPD DRINK

Glavne informacije

  • Zaščiteno ime:
  • Survimed OPD drink vanilija EasyBottle 200 ml 4x
  • Farmacevtska oblika:
  • peroralna suspenzija
  • Enote v paketu:
  • škatla s 4 plastenkami z 200 ml napitka (EasyBottle)
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • Survimed OPD drink vanilija EasyBottle 200 ml 4x
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Živilo
  • Zadnja posodobitev:
  • 18-01-2018

Podatki za bolnike

Survimed OPD drink

okus: vanilija

100 kcal/100 ml

vsebina: 4 x 200 ml (4 x 200 kcal/840 kJ)

Dietetično živilo za posebne zdravstvene namene. Prehransko popoln normokaloričen (1 kcal/ml),

nizkomolekularen oligopeptidni pripravek za pitje. Vsebuje hidrolizirane sirotkine beljakovine, ki se

popolnoma absorbirajo. 48 % vseh maščob predstavljajo MCT. Brez glutena, brez vlaknin, vsebuje

zelo malo laktoze. Za dietetsko uravnavanje bolnikov z malabsorpcijo.

Odmerjanje: Kot edini vir prehrane 7–8 plastenk/dan, kot dopolnilna prehrana 2–3 plastenke/dan.

Pomembna opozorila: Uporabljajte le pod zdravniškim nadzorom. Izdelek ni primeren za otroke do 3 let.

Pijte počasi! Živilo je najbolj okusno, če je ohlajeno. Pred uporabo dobro pretresite! Ni za parenteralno

uporabo! Pakirano v kontrolirani atmosferi.

Shranjevanje: Shranjujte pri sobni temperaturi. Odprte plastenke lahko shranjujete v hladilniku do 24 ur.

Povprečna

vsebnost

na

100 ml:

energijska

vrednost

(420 kJ) 100 kcal,

maščobe

2,8 g

(nasičene

maščobne

kisline

1,46 g,

1,33 g,

mononenasičene

maščobne

kisline

0,79 g,

polinenasičene

maščobne

kisline

0,55 g),

ogljikovi

hidrati

14,1 g

(sladkorji

5,0 g,

laktoza

0,1 g),

vlaknine

0,1 g,

beljakovine 4,65 g, voda 85 ml, osmolarnost 410 mosmol/l.

Energijski deleži: maščobe 25 %, ogljikovi hidrati 56,4 %, vlaknine 0 %, beljakovine 18,6 %.

Minerali in elementi v sledovih: Na 80 mg (3,5 mmol) (**), K 200 mg (5,1 mmol) (*10,0), Cl 83 mg

(2,3 mmol) (*10,4), Ca 65 mg (1,6 mmol) (*8,1), Mg 25 mg (1 mmol) (*6,7), P 48 mg (1,5 mmol) (*6,9),

Fe 1,3 mg (*9,3), Zn 1,2 mg (*12,0), Cu 133 µg (*13,3), Mn 0,27 mg (*13,5), I 13,3 µg (*8,9), F 0,13 mg

(*3,7), Cr 6,7 µg (*16,8), Mo 10 µg (*20,0), Se 6,7 µg (*12,2).

Vitamini: vit. A 70 µg RE (*8,8),

-karoten 133 μg (**), vit. D

1,0 µg (*20,0), vit. K

6,7 µg (*8,9), vit. E

1,3 mg α-TE (*10,8), vit. B

0,13 mg (*11,8), vit. B

0,17 mg (*12,1), niacin 1,6 mg NE (*10,0), vit. B

0,16 mg (*11,4), vit. B

0,27 µg (*10,8), pantotenska kislina 0,47 mg (*7,8), biotin 5,0 µg (*10,0), folna

kislina 26,7 µg (*13,4), vit. C 8,0 mg (*10,0), holin 36,7 mg (**).

Sestavine: voda, maltodekstrin, hidrolizat sirotkinih beljakovin, saharoza, rastlinska olja (repično olje, olje

barvilnega rumenika), nasičeni srednjeverižni trigliceridi (MCT), arome, kalijev hidrogenfosfat, kalcijev citrat,

natrijev klorid, stabilizatorji (E460, E466), holinijev klorid, vit. C, magnezijev oksid, kalijev klorid, emulgator

(E472c), cinkov sulfat, železov sulfat, niacin, vit. E, manganov klorid, pantotenska kislina, bakrov sulfat,

natrijev fluorid, vit. B

, vit. B

, vit. B

-karoten, vit. A, folna kislina, kromov klorid, natrijev molibdat, natrijev

selenit, vit. K

, biotin, kalijev jodid, vit. D

, vit. B

*delež (%) priporočenega dnevnega vnosa PDV (RDA); **PDV ni določen

Uporabno najmanj do konca: označeno na originalni ovojnini

Distributer: Medias International d.o.o., Leskoškova cesta 9D, 1000 Ljubljana

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

29-10-2018

Aurobindo Pharma Limited Issues Voluntary Recall of Irbesartan Drug Substance due to the Detection of Trace Amounts of NDEA (NNitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Aurobindo Pharma Limited Issues Voluntary Recall of Irbesartan Drug Substance due to the Detection of Trace Amounts of NDEA (NNitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Aurobindo Pharma Limited is voluntarily recalling 22 Batches of the drug substance Irbesartan due to the presence of an impurity, N-nitrosodiethylamine (NDEA). The impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC).

FDA - U.S. Food and Drug Administration

26-10-2018

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Published on: Thu, 25 Oct 2018 00:00:00 +0200 The product subject of this assessment is l‐threonine produced by fermentation with a genetically modified strain of Escherichia coli (CGMCC 7.232). It is intended to be used in feed and water for drinking for all animal species and categories. The production strain and its recombinant DNA were not detected in the additive. The product l‐threonine, manufactured by fermentation with E. coli CGMCC 7.232, does not raise any safety concern with regard to the gen...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Health Canada reminds Canadians not to mix caffeinated drinks with alcohol

Health Canada reminds Canadians not to mix caffeinated drinks with alcohol

September 27, 2018 Ottawa Health Canada

Health Canada

22-8-2018

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industr...

FDA - U.S. Food and Drug Administration

18-8-2018

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probabl...

FDA - U.S. Food and Drug Administration

27-7-2018

Pending EC decision:  Opdivo, nivolumab, Opinion date: 26-Jul-2018

Pending EC decision: Opdivo, nivolumab, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

17-7-2018

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical. The impurity detected in the API is N- nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking wat...

FDA - U.S. Food and Drug Administration

6-7-2018

Blokhuis: maatregelen nodig tegen probleemgebruik energiedrankjes

Blokhuis: maatregelen nodig tegen probleemgebruik energiedrankjes

Een relatief kleine groep jongeren tussen de 13 en 18 jaar drinkt te veel energiedrank en loopt daarmee risico op gezondheidsklachten. Dat blijkt uit onderzoek dat het RIVM uitvoerde in opdracht van staatssecretaris Paul Blokhuis (VWS) naar aanleiding van signalen van kinderartsen eerder dit jaar. Over het algemeen is de consumptie van energiedrankjes onder jongeren de afgelopen jaren afgenomen. Vier op de vijf jongeren drinkt het nooit of minder dan wekelijks.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

29-6-2018

Pending EC decision:  Opdivo, nivolumab, Opinion date: 28-Jun-2018

Pending EC decision: Opdivo, nivolumab, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

12-6-2018

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Teer, nicotine en koolmonoxide gehalten in sigaretten die gemeten worden volgens de Canadian Intense (CI) methode zijn minimaal twee keer zo hoog als de gehalten gemeten met de wettelijke voorgeschreven ISO methode waarmee de EU en dus ook Nederland werkt. In sommige gevallen liggen de gehaltes zelfs tot meer dan 20 keer hoger. Dat blijkt uit onderzoek van het RIVM, dat 100 sigaretten onder de loep nam. Staatssecretaris Paul Blokhuis (VWS) heeft als opdrachtgever het onderzoek vandaag in ontvangst genome...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

1-5-2018

Do You Vape? See These Tips on How to Keep E-Liquids Away from Children

Do You Vape? See These Tips on How to Keep E-Liquids Away from Children

Accidentally touching or drinking e-liquids can be dangerous and even deadly for young children. So it’s important to handle and store these products carefully, to teach children to stay away from these products, and to be prepared for emergencies. Consider these tips.

FDA - U.S. Food and Drug Administration

1-8-2018

Opdivo (Bristol-Myers Squibb Pharma EEIG)

Opdivo (Bristol-Myers Squibb Pharma EEIG)

Opdivo (Active substance: nivolumab) - Centralised - 2-Monthly update - Commission Decision (2018)5204 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3985/II/41

Europe -DG Health and Food Safety

27-7-2018

Withdrawn application:  Opdivo, nivolumab, Post-authorisation

Withdrawn application: Opdivo, nivolumab, Post-authorisation

Europe - EMA - European Medicines Agency

29-6-2018

FDA approves novel device for treating breathing difficulties associated with severe emphysema-  https://go.usa.gov/xUYXd  #FDA #MedicalDevice #COPDpic.twitter.com/do1EG38wMM

FDA approves novel device for treating breathing difficulties associated with severe emphysema- https://go.usa.gov/xUYXd  #FDA #MedicalDevice #COPDpic.twitter.com/do1EG38wMM

FDA approves novel device for treating breathing difficulties associated with severe emphysema- https://go.usa.gov/xUYXd  #FDA #MedicalDevice #COPD pic.twitter.com/do1EG38wMM

FDA - U.S. Food and Drug Administration

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration